drugset / Trial / NCT03517631
An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells that stably express multiplexed shRNA to treat HIV infection.
Timeline
- Start
- 2018-02-27
- Primary completion
- 2020-12-15
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 1 mg/kg | — |
| Subject | shRNA-modified CD34+ cells | Cell therapy | — | — |